GV, Alphabet Inc's venture capital arm, led a US$58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.
The company said it will only develop treatments that involve editing adult cells, so the effects of genetic manipulation cannot be passed on to future generations.
Vi har sammanfattat den här nyheten så att du kan läsa den snabbt. Om du är intresserad av nyheterna kan du läsa hela texten här. Läs mer:
Sverige Senaste nytt, Sverige Rubriker
Similar News:Du kan också läsa nyheter som liknar den här som vi har samlat in från andra nyhetskällor.
Brazil cosmetics company Natura to invest US$5m in new brands through venture capital funds[SAO PAULO] Brazil cosmetics company Natura intends to invest up to US$5 million in new brands in beauty and wellness segments in Europe and the United States through venture capital funds, executives said on Friday. Read more at The Business Times.
Källa: BusinessTimes - 🏆 15. / 51 Läs mer »
More funds to help companies train workers, raise wages
Källa: TODAYonline - 🏆 1. / 99 Läs mer »
More funding for companies that work with unions to prepare workers for transformation: DPM HengSINGAPORE - Technological advancements should help workers do their jobs better, not replace them, said Deputy Prime Minister Heng Swee Keat on Wednesday (May 1).. Read more at straitstimes.com.
Källa: The Straits Times - 🏆 8. / 63 Läs mer »